Insider buying last 90 days
No open-market insider purchases were filed for ROIV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ROIV insider filing, plotted on the chart in Gekko.Open ROIV in Gekko
NASDAQ: ROIV
Roivant Sciences (ROIV) Stock Analysis & Forecast
Nov 4 close
$38.23+2.19 (+6.1%)
Gekko Brief
AI summaryNov 4 closeRoivant Sciences moves this week on the Phase 3 win for brepocitinib in non-infectious uveitis, announced with Priovant Therapeutics, meeting primary and key secondary endpoints with a favorable safety profile. Citi raised its price target on ROIV to $56 from $46 while maintaining a Buy rating, citing a stronger valuation perspective and confidence in the company's strategic direction. Separately, a Form 144 notice disclosed that officer Eric Venker plans to sell 200,000 shares valued at $7.26 million.
ROIV closed at $38.23, up 6.1%, sitting above both its 50-day average of $36.67 and its 200-day average of $31.71, with the 50-day above the 200-day. The GekkoIndex reads 54, placing the stock in the Neutral zone. Price sits close to Gekko Fair Value of $38.68, a gap of -1.2%.
Earnings are due 9 November 2026, before the open, just 4 days away and inside a typical 20-trading-day holding window; the prior quarter saw a 5% reaction on an in-line EPS result. Over the last 30 days there has been 1 unusual options signal, with call premium of $631,090 against no put premium. Seasonally, the next 20 trading days have averaged +8.7% over 5 years, rising in 5 of them. Analyst coverage stands at 10 buy and 2 hold ratings among 12 firms, with a consensus target of $50.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Roivant Sciences price vs fair value
Close $38.23200-day averageGekko Fair Value $38.68
Roivant Sciences quick facts
- Market cap
- $27.61B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.52
- Revenue, TTM
- $7.53M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.20
- Volume
- 11.67M avg 6.92M
- 1-year return
- +95.1%
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±7.8%
- 50-day average
- $36.67
- 200-day average
- $31.71
- Next earnings
- Nov 9 before open
- Shares outstanding
- 722.3M
Roivant Sciences swing-trade checklist
Roivant Sciences scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $38.23 is above the 50-day ($36.67) and 200-day ($31.71) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54, Neutral
Reading 54 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
1.2% below
Price is within 5% of Gekko Fair Value (1.2% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings riskheadwind
Reports in 4 days
Reports on Nov 9, 2026, 4 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+8.7% on average
From this point in the calendar, the next 20 trading days averaged +8.7% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Roivant Sciences stock chart and price history
Roivant Sciences closed at $38.23 on Nov 4, 2026, +95.1% over the past year, inside a 52-week range of $19.32 to $42.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.6%
- 3 months
- +8.9%
- 6 months
- +32.7%
- 1 year
- +95.1%
The full ROIV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ROIV in Gekko
Follow Roivant Sciences through every session
Put ROIV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ROIV in GekkoFree for 7 days. No credit card required.
Roivant Sciences GekkoIndex: the smart money zone
Roivant Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54, in the Neutral zone, up 0.3 points over five sessions.
54Neutral
Up 0.3 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | +1.8% | +12.6% | ||
| Accumulation | 176 | +2.3% | +4.4% | ||
| Neutral (current zone) | 428 | +0.3% | +3.5% | ||
| Distribution | 71 | +2.2% | +4.0% | ||
| Selling | 2 | Too few readings yet | |||
Average ROIV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ROIV price, zone by zone.Track ROIV in Gekko
Is Roivant Sciences stock overvalued? Gekko Fair Value
Roivant Sciences trades 1.2% below Gekko Fair Value of $38.68, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Roivant Sciences shares are worth, recalculated every trading day.
$38.68
Gekko Fair Value, Nov 4, 2026
1.2% below fair value · About fair value
At the end of Aug 2026 the price was 12.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ROIV in Gekko
Roivant Sciences insider and Congress trading
No open-market insider purchases were filed for Roivant Sciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ROIV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ROIV, plotted on the chart in Gekko.Open ROIV in Gekko
Buybacks
Roivant Sciences has been buying back its own shares.
- Latest authorization
- $1.00B, Mar 3, 2026
- Bought back, quarter ended Jun 30, 2026
- $206.7M
- As a share of market cap
- 0.75%
From company filings.
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Oct 7, $631K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ROIV.
0added0opened1trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Roivant Sciences earnings: next date and track record
Roivant Sciences reports on Nov 9, 2026, before the open (4 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 4 days away
- EPS estimate
- −$0.37
- Revenue estimate
- $4.15M
5 of 8reports beat the EPS estimate
±7%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Roivant's Q1 FY2026 was described as a quiet quarter with steady pipeline progress. Key highlights include enrollment in Phase III cutaneous sarcoidosis study for brepocitinib, receipt of initial Moderna settlement payment, and brepocitinib expected to launch in dermatomyositis by end of September 2026. Phase II data showed >20-point CSAMI benefit vs. placebo. LPP added as a fourth brepocitinib indication with strong enrollment.
- Guidance
- Management expects a busy second half with brepocitinib DM launch imminent, top-line data from NIU study, mosli Phase II in PH-ILD, D2T RA program FDA updates, and CLE POC data all expected H2 2026. Graves disease data anticipated in 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.45 est −$0.45 | $1.44M est $2.06M | +5.0% |
| May 20, 2026 | −$0.32 est −$0.35 | $2.52M est $3.41M | +9.5% |
| Feb 6, 2026 | −$0.24 est −$0.30 | $2.00M est $5.08M | +30.9% |
| Nov 10, 2025 | −$0.28 est −$0.32 | $1.57M est $5.62M | +1.4% |
| Aug 11, 2025 | −$0.25 est −$0.23 | $2.17M est $7.30M | +0.7% |
| May 29, 2025 | −$0.22 est −$0.26 | $7.57M est $54.07M | +3.5% |
| Feb 10, 2025 | $0.23 est −$0.28 | $9.02M est $62.17M | −3.7% |
| Nov 12, 2024 | −$0.31 est −$0.26 | $4.48M est $45.92M | +1.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Roivant Sciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Roivant Sciences is $50.00, +30.8% from the last close, from 12 firms rating the stock in the last 90 days.
$50.00consensus 12-month target, +30.8% from the last close
Now $38.23Avg $50.00
Low $40High $62
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Leerink Partners | $54 | +41.3% |
| Oct 29 | Citi | $56 | +46.5% |
| Oct 28 | Citi | $56 | +46.5% |
| Oct 21 | H.C. Wainwright | $47 | +22.9% |
| Oct 21 | TD Cowen | $62 | +62.2% |
+3.5%average 20-day move after past Neutral readings
+8.7%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Roivant Sciences seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Roivant Sciences averaged +8.7% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 2 of 5 |
| Next 10 trading days | −1.7% | 2 of 5 |
| Next 15 trading days | −1.6% | 2 of 5 |
| Next 20 trading days | +8.7% | 5 of 5 |
| Next 30 trading days | +19.4% | 5 of 5 |
For scale, ROIV’s typical 20-trading-day move in either direction is about 7.8%.
Roivant Sciences market cap and key statistics
Roivant Sciences’s market cap is $27.61B and revenue of $7.53M over the last twelve months.
Valuation
- Market cap
- $27.61B
- EPS, TTM
- −$0.52
- Gekko Fair Value
- $38.68
Trading
- Volume
- 11.67M
- Avg volume, 20 days
- 6.92M
- 52-week high
- $42.50
- 52-week low
- $19.32
- Shares outstanding
- 722.3M
Financials
- Revenue, TTM
- $7.53M
- Profit margin
- 0%
- Return on equity
- -8.5%
- Quarterly earnings growth, YoY
- −96.1%
Risk and income
- Beta
- 1.20
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±7.8%
Roivant Sciences stock news this week
Coverage of Roivant Sciences this week reads positive: 4 positive, 4 neutral and 2 negative headlines.
- Roivant Sciences Officer Eric Venker to Sell 200,000 Shares Valued at $7.26 MillionKalkine Media, Nov 4
- Technical Reactions to ROIV Trends in Macro StrategiesStock Traders Daily, Nov 3
- How Investors May Respond To Roivant Sciences (ROIV) Phase 3 Uveitis WinSimply Wall St, Oct 31
- Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 28 OctoberInvesting.com Canada, Oct 30
- Roivant Sciences Ltd. Tokenized Stock (Ondo) price today, ROIVon to USD live price, marketcap and chartCoinMarketCap, Oct 30
- A six-figure gift goes to No Patient Left Behind as Roivant Social Ventures closes its institutional work.Stock Titan, Oct 29
Roivant Sciences peers
Roivant Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Roivant Sciences stock FAQ
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $27.61B at the Nov 4, 2026 close of $38.23, with 722.3M shares outstanding.
What is the Roivant Sciences stock forecast?
The consensus analyst 12-month price target for Roivant Sciences is $50.00, +30.8% from the last close. Of the 12 firms that rated the stock in the last 90 days, 10 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Roivant Sciences stock overvalued or undervalued?
On Gekko’s estimate Roivant Sciences is about fair value: the Nov 4, 2026 close of $38.23 is 1.2% below Gekko Fair Value of $38.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Roivant Sciences report earnings next?
Roivant Sciences is expected to report on Nov 9, 2026, before the market opens (4 days away). Analysts expect earnings of −$0.37 per share on revenue of $4.15M. Roivant Sciences beat the earnings estimate in 5 of its last 8 reports, moving 7% on average across the report.
What is Roivant Sciences’s 52-week high and low?
Roivant Sciences’s 52-week high is $42.50 and its 52-week low is $19.32; it closed at $38.23 on Nov 4, 2026, +95.1% over the past year.
Is Roivant Sciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Roivant Sciences?
Gekko flagged 1 unusual options signal in Roivant Sciences over the last 30 days, with $631K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 7, 2026 with $631K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Roivant Sciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.